Stephen Poyer
Population Services International
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Stephen Poyer.
Malaria Journal | 2011
Kathryn A O'Connell; Hellen W Gatakaa; Stephen Poyer; Julius Njogu; Illah Evance; Erik Munroe; Tsione Solomon; Catherine Goodman; Kara Hanson; Cyprien Zinsou; Louis Akulayi; Jacky Raharinjatovo; Ekundayo D. Arogundade; Peter Buyungo; Felton Mpasela; Chérifatou Bello Adjibabi; Jean Angbalu Agbango; Benjamin Ramarosandratana; Babajide Coker; Denis Rubahika; Busiku Hamainza; Steven Chapman; Tanya Shewchuk; Desmond Chavasse
BackgroundArtemisinin-based combination therapy (ACT) is the first-line malaria treatment throughout most of the malaria-endemic world. Data on ACT availability, price and market share are needed to provide a firm evidence base from which to assess the current situation concerning quality-assured ACT supply. This paper presents supply side data from ACTwatch outlet surveys in Benin, the Democratic Republic of Congo (DRC), Madagascar, Nigeria, Uganda and Zambia.MethodsBetween March 2009 and June 2010, nationally representative surveys of outlets providing anti-malarials to consumers were conducted. A census of all outlets with the potential to provide anti-malarials was conducted in clusters sampled randomly.Results28,263 outlets were censused, 51,158 anti-malarials were audited, and 9,118 providers interviewed. The proportion of public health facilities with at least one first-line quality-assured ACT in stock ranged between 43% and 85%. Among private sector outlets stocking at least one anti-malarial, non-artemisinin therapies, such as chloroquine and sulphadoxine-pyrimethamine, were widely available (> 95% of outlets) as compared to first-line quality-assured ACT (< 25%). In the public/not-for-profit sector, first-line quality-assured ACT was available for free in all countries except Benin and the DRC (US
Malaria Journal | 2011
Megan Littrell; Hellen W Gatakaa; Illah Evance; Stephen Poyer; Julius Njogu; Tsione Solomon; Erik Munroe; Steven Chapman; Catherine Goodman; Kara Hanson; Cyprien Zinsou; Louis Akulayi; Jacky Raharinjatovo; Ekundayo D. Arogundade; Peter Buyungo; Felton Mpasela; Chérifatou Bello Adjibabi; Jean Angbalu Agbango; Benjamin Ramarosandratana; Babajide Coker; Denis Rubahika; Busiku Hamainza; Tanya Shewchuk; Desmond Chavasse; Kathryn A O'Connell
1.29 [Inter Quartile Range (IQR):
Malaria Journal | 2013
K O’Connell; Stephen Poyer; Tsione Solomon; Erik Munroe; Edith Patouillard; Julius Njogu; Illah Evance; Kara Hanson; Tanya Shewchuk; Catherine Goodman
1.29-
Tropical Medicine & International Health | 2015
Stephen Poyer; Tanya Shewchuk; Sarah Tougher; Yazoume Ye; Andrea Mann; Barbara Willey; Rebecca Thomson; John H Amuasi; Ruilin Ren; Marilyn Wamukoya; Mark Taylor; Samuel Blay Nguah; Blessing Mberu; Admirabilis Kalolella; Elizabeth Juma; Charles Festo; Boniface Johanes; Graciela Diap; Katia Bruxvoort; Daniel Ansong; Kara Hanson; Fred Arnold; Catherine Goodman
1.29] and
PLOS ONE | 2017
Theodoor Visser; Katia Bruxvoort; Kathleen Maloney; Toby Leslie; Lawrence M. Barat; Richard Allan; Evelyn K. Ansah; Jennifer Anyanti; Ian Boulton; Siân E. Clarke; Jessica Cohen; Justin M. Cohen; Andrea Cutherell; Caitlin Dolkart; Katie Eves; Günther Fink; Catherine Goodman; Eleanor Hutchinson; Sham Lal; Anthony K. Mbonye; Obinna Onwujekwe; Nora Petty; Julie Pontarollo; Stephen Poyer; David Schellenberg; Elizabeth Streat; Abigail Ward; Virginia Wiseman; Christopher J. M. Whitty; Shunmay Yeung
0.52[IQR:
Health Policy and Planning | 2016
B Palafox; Edith Patouillard; Sarah Tougher; Catherine Goodman; Kara Hanson; Immo Kleinschmidt; Sergio Torres Rueda; Sabine Kiefer; Kate O’Connell; Cyprien Zinsou; Sochea Phok; Louis Akulayi; Ekundayo D. Arogundade; Peter Buyungo; Felton Mpasela; Stephen Poyer; Desmond Chavasse
0.00-
PLOS ONE | 2018
Christina Riley; Danielle Garfinkel; Katherine Thanel; Keith Esch; Endale Workalemahu; Jennifer Anyanti; Godéfroid Mpanya; Arsene Binanga; Jen Pope; Kim Longfield; Jane T. Bertrand; Bryan Shaw; Andrew Andrada; Eric Auko; Katie Bates; Nirali Chakrabory; Desmond Chavasse; Tarryn Haslam; Catherine Hurley; Tabeth Jiri; Aliza Lailari; Megan Littrell; Julius Ngigi; Kathryn A O'Connell; Ricki Orford; P. Prabhu; Stephen Poyer; Justin Rahariniaina; Mac Shoen; Habtamu Tamene
1.29] per adult equivalent dose respectively). In the private sector, first-line quality-assured ACT was 5-24 times more expensive than non-artemisinin therapies. The exception was Madagascar where, due to national social marketing of subsidized ACT, the price of first-line quality-assured ACT (
Malaria Journal | 2018
Hannah Koenker; Fred Arnold; Fatou Ba; Moustapha Cisse; Lamine Diouf; Erin Eckert; Marcy Erskine; Lia Florey; Megan Fotheringham; Lilia Gerberg; Christian Lengeler; Matthew Lynch; Abraham Mnzava; Susann Nasr; Medoune Ndiop; Stephen Poyer; Melanie Renshaw; Estifanos Shargie; Cameron Taylor; Julie Thwing; Suzanne Van Hulle; Yazoume Ye; Josh Yukich; Albert Kilian
0.14 [IQR:
Malaria Journal | 2014
Megan Littrell; Raymond Sudoi; Julie Archer; Julius Ngigi; Chinazo Ujuju; Godéfroid Mpanya; Vamsi Vasireddy; Stephen Poyer; Hana Bilak
0.10,
Malaria Journal | 2017
Louis Akulayi; Angela Alum; Andrew Andrada; Julie Archer; Ekundayo D. Arogundade; Erick Auko; Abdul R. Badru; Katie Bates; Paul Bouanchaud; Meghan Bruce; Peter Buyungo; Angela Camilleri; Emily Carter; Steven Chapman; Nikki Charman; Desmond Chavasse; Robyn Cyr; Kevin Duff; Gylsain Guedegbe; Keith Esch; Illah Evance; Anna Fulton; Hellen Gataaka; Tarryn Haslam; Emily Harris; Christine Hong; Catharine Hurley; Whitney Isenhower; Enid Kaabunga; Baraka D. Kaaya
0.57]) was significantly lower than the most popular treatment (chloroquine,
Collaboration
Dive into the Stephen Poyer's collaboration.
